Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
I wonder if it will remove the text in links? Only one way to find out….
Here goes!
https://en.m.wikipedia.org/wiki/Twatt,_Shetland
i wouldn’t get your knickers in a twist over a few asterisks covering four letter words. it’s the old and crude software used by lse - no human or algorithm involved. it’s a built-in feature that’s common to many bulletin boards that use this ancient piece of software.
if you live in s****horpe you’ll never be able to say so!
Good post Brighty, just not sure why you added (covid) after COPD? They’re two completely different thIngs. COPD( Chronic obstructive pulmonary disease ) is often caused by contamination or pollution from the environment (typically inhalation in the workplace) or smoking; whereas covid is of course a viral infection. Their treatment is also different. Whether there’s any crossover with Salmeterol as a treatment appears to be a complex question, but I don’t see any direct link with Salmeterol for covid unless there’s a pre-existing respiratory condition.
Apologies for being a bit long winded, it’s just that I have a personal interest in COPD as well as other respiratory conditions and Salmeterol.
HRS-1167 Is a phase 1 asset, so a license for, say, 1801 might align to these figures.
But 737 is a phase 2 asset and potentially worth more
https://www.fiercebiotech.com/biotech/merck-pays-169m-selective-parp1-drug-stepping-challenge-astrazeneca-and-gilead
As you mentioned, Ben, Pandion…
https://www.fiercebiotech.com/biotech/pandion-s-secret-to-moving-a-65m-merck-offer-to-a-1-9b-done-deal-a-year-just-keep-saying-no#:~:text=Just%20keep%20saying%20no,-By%20Ben%20Adams&text=If%20you%20want%20Merck%20to,to%20do%20is%20play%20hardball.
Couldn’t leave that question hanging tHere, unanswered, potnak!
https://www.merck.com/news/keytruda-pembrolizumab-mercks-anti-pd-1-therapy-demonstrates-superior-survival-progression-free-survival-and-overall-response-rate-compared-to-ipilimumab-an-anti-ctla-4-therapy/
Well, the normal format appears to be an up-front fee plus milestone payments and/or sales based royalties.
However, after phase 2 it can get particularly interesting. Look at how Nimbus spun off their TYK2 division in a $4Bn sale to Takeda.
That’s why it’s an open question and that’s why the answer is “depends”. There’s so many possibilities.
Jerryjw/RMM: Apologies if I’ve got the wrong end of the stick here, but wasn’t Tim referring to the Takeda acquisition of the TYK2 part of Nimbus Theraputics which has a price tag of $4Bn plus a potential further $2Bn?
https://www.takeda.com/newsroom/newsreleases/2023/takeda-completes-acquisition-of-nimbus-therapeutics-tyk2-program-subsidiary/
The BMS comment was in respect of the FDA approval of Sotyktu / deucravacitinib effectively derisking the TYK2 space by precedent:
https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Announces-New-Sotyktu-deucravacitinib-Long-Term-Data-Showing-Clinical-Efficacy-Maintained-for-Up-to-Two-Years-with-Continuous-Treatment-in-Moderate-to-Severe-Plaque-Psoriasis/default.aspx
Aber, if there are NDAs in place for 737 negotiations, then “not knowing the status” wouldn’t be “BS” would it?
There are so many scenarios imaginable, almost all of them wrapped up in NDAs so that our BoD would not, could not know how they are progressing.